Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14213482 | 1.00 | HRH3 (0.48) | HRH3SLC18A3KDM1AHTTKCNH2 | |
| SCHEMBL10057687 | 0.86 | SLC18A3 (0.57) | HRH3SLC18A3KDM1AHTTKCNH2 | |
| SCHEMBL8025619 | 0.86 | KDM1A (0.51) | HRH3KDM1AKCNH2KIF11SLC6A3 | |
| SCHEMBL8037056 | 0.86 | KDM1A (0.51) | HRH3KDM1AKCNH2KIF11SLC6A3 | |
| SCHEMBL14213478 | 0.79 | HRH3 (0.49) | HRH3KDM1AKCNH2KIF11SLC6A3 | |
| SCHEMBL17086699 | 0.79 | HRH3 (0.49) | HRH3KDM1AKCNH2KIF11SLC6A3 | |
| SCHEMBL18022013 | 0.79 | MAOB (0.52) | HRH3KDM1AKCNH2KIF11MAPT | |
| SCHEMBL22962229 | 0.79 | MAOB (0.52) | HRH3KDM1AKCNH2KIF11MAPT | |
| SCHEMBL21787710 | 0.79 | HRH3 (0.49) | HRH3KDM1AKCNH2KIF11SLC6A3 | |
| SCHEMBL14627075 | 0.79 | HRH3 (0.49) | HRH3KDM1AKCNH2KIF11SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309773-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | JAK2, JAK1, JAK3 | HRH3 1736/4885SLC18A3 4859/4885KDM1A 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.